This Article  • Full text  • PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Citing articles on Web of Science (49)  • Contact me when this article is cited  Related Content  • Related article  • Similar articles in this journal  Topic Collections  • Review  • Genetics  • Genetic Disorders  • Coagulation Disorders  • Alert me on articles by topic  Social Bookmarking   What's this?

Robert H. Thomas, MD

Arch Intern Med. 2001;161:2433-2439.

Hypercoagulability can be defined as the tendency to have thrombosis as a result of certain inherited and/or acquired molecular defects. Clinical manifestations of hypercoagulability can be devastating and even lethal. In the past 20 years, the origin of most of these diverse hypercoagulability syndromes has been elucidated. Currently, hypercoagulability disorders can be correctly diagnosed in approximately 80% to 90% of patients. Defining the cause of hypercoagulability may determine the type and duration of treatment for the associated thrombosis. The discovery of an occult carcinoma allows for the possibility of early and possibly curative treatment. Finding a genetic defect in coagulation allows for testing of asymptomatic family members as well. The purpose of this review is to provide internists with a logical approach to the identification and treatment of hypercoagulability syndromes.

From the Department of General Medicine, University of Miami School of Medicine, Miami, Fla.

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?

RELATED ARTICLE

Archives of Internal Medicine Reader's Choice: Continuing Medical Education
Arch Intern Med. 2001;161(20):2511-2512.
FULL TEXT  

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Autoimmune-mediated atherothrombosis
Matsuura and Lopez
Lupus 2008;17:879-888.
ABSTRACT  

Tissue factor in the antiphospholipid syndrome
Kinev and Roubey
Lupus 2008;17:953-959.
ABSTRACT  

Evaluation of anticoagulation in patients with antiphospholipid syndrome
Horner et al.
Am J Health Syst Pharm 2008;65:964-967.
ABSTRACT | FULL TEXT  

Stroke and antiphospholipid syndrome: the treatment debate
Ruiz-Irastorza and Khamashta
Rheumatology (Oxford) 2005;44:971-974.
ABSTRACT | FULL TEXT  

Hematology in palliative medicine
Davis
AM J HOSP PALLIAT CARE 2004;21:445-454.
ABSTRACT  

Antiphospholipid Syndrome Associated with Malignant Mesothelioma Presenting with Superior Vena Cava Thrombosis: A Case Report
Ozkan et al.
CLIN APPL THROMB HEMOST 2004;10:393-396.
ABSTRACT  

A 47-year-old man with mesothelioma and neck swelling
Schattner and Kozack
CMAJ 2004;170:465-465.
FULL TEXT  

Duration of Anticoagulant Therapy After Initial Idiopathic Venous Thromboembolism
Frazee and Chomo
The Annals of Pharmacotherapy 2003;37:1489-1496.
ABSTRACT | FULL TEXT  

Genetic Hypercoagulability Syndromes: Does Testing Really Matter?
Procopiou
Arch Intern Med 2002;162:1784-1785.
FULL TEXT  

Hypercoagulable Disorders
Goichot et al.
Arch Intern Med 2002;162:1785-1787.
FULL TEXT  

The Clot Thickens! In Thin Air
Kashyap and Kashyap
Arch Intern Med 2002;162:1783-1783.
FULL TEXT  

Antiphospholipid Antibodies
Moll and Ortel
Arch Intern Med 2002;162:1783-1784.
FULL TEXT